U.S. Markets closed

Sanofi (SNY)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
49.29-0.30 (-0.60%)
At close: 4:02PM EDT
People also watch
Full screen
Previous Close49.59
Bid49.32 x 100
Ask49.52 x 100
Day's Range49.28 - 49.61
52 Week Range36.81 - 50.24
Avg. Volume1,889,431
Market Cap117.26B
PE Ratio (TTM)12.17
EPS (TTM)4.05
Earnings DateN/A
Dividend & Yield1.64 (3.33%)
Ex-Dividend Date2017-05-11
1y Target Est51.75
Trade prices are not sourced from all markets
  • Barrons.com7 hours ago

    Regeneron: The More the Merrier?

    Last week we noted that when a stock has a big rally, analysts are forced to either cut their rating or raise their target price. Today, Leerink's Geoffrey Porges and Bradley Canino raise their Regeneron target to $573 from $483: After lots of news in the last week, and a major shift in value, and expectations, we are updating our Regeneron model to incorporate higher expected sales of Dupixent (including adult atopic dermatitis, pediatric atopic dermatitis, high eosinophil and non-eosinophilic asthma), lower expected sales of Eylea (accounting for some erosion by RTH258 starting in 2019), and including for the first time revenue from REGN2810, which is the company’s joint (with Sanofi (SNY)) PD-1 antibody.

  • Sanofi/Regeneron's Kevzara Gets Marketing Approval in EU
    Zacks7 hours ago

    Sanofi/Regeneron's Kevzara Gets Marketing Approval in EU

    Sanofi (SNY) and partner Regeneron Pharmaceuticals, Inc. (REGN) announced that the European Commission has granted marketing approval to its rheumatoid arthritis (RA) drug Kevzara.

  • Amgen Gets Positive CHMP Opinion for Mimpara Label Expansion
    Zacks7 hours ago

    Amgen Gets Positive CHMP Opinion for Mimpara Label Expansion

    Amgen announced that the European Medicines Agency's Committee for Medicinal Products for Human Use has rendered a positive opinion recommending marketing approval of a pediatric formulation of Mimpara for the treatment of secondary hyperparathyroidism